SCHEMBL5455299

SCHEMBL5455299

c1cc2c(c(N3CCNCC3)c1)CCCOO2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 5/20 0.51
HTR6 P50406 2/20 0.42
HTR7 P34969 2/20 0.42
DRD2 P14416 1/20 0.42
DRD3 P35462 1/20 0.42
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
CYP1A2 P05177 1/20 0.42
HTR1A P08908 1/20 0.42
CYP2D6 P10635 1/20 0.42
NCF1 P14598 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
HTR2A P28223 1/20 0.42
MTOR P42345 1/20 0.42
HTR3A P46098 1/20 0.42
HTR5A P47898 1/20 0.42
HTR3D Q70Z44 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6193067 0.91 ADRB1 (0.54) ADRB1HTR6HTR7DRD2DRD3
Hydrochloric Acid SCHEMBL9466548 0.90 ADRB1 (0.52) ADRB1HTR6HTR7DRD2DRD3
Hydrochloric Acid SCHEMBL4634216 0.90 ADRB1 (0.52) ADRB1HTR6HTR7DRD2DRD3
SCHEMBL3925000 0.85 ADRB1 (0.61) ADRB1HTR6HTR7DRD2DRD3
SCHEMBL27364182 0.83 ADRB1 (0.44) ADRB1HTR6HTR7DRD2DRD3
SCHEMBL6601483 0.81 ADRB1 (0.60) ADRB1HTR6HTR7DRD2DRD3
SCHEMBL5368588 0.79 ADRB1 (0.65) ADRB1HTR6HTR7DRD2DRD3
Hydrochloric Acid SCHEMBL27237927 0.78 ADRB1 (0.63) ADRB1HTR6HTR7DRD2DRD3
SCHEMBL8691571 0.74 MTNR1A (0.36) ADRB1
SCHEMBL2348878 0.72 ADRB1 (0.53) ADRB1HTR6HTR7DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070117788-A1 Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-05-24 US disclosed
EP-1397134-A2 COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEROF FOR TREATING OBSTRUCTIVE AIRWAYS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-03-17 EP disclosed
WO-2002096422-A2 COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117788-A1 Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases CHRM2, ADRB2, CHRM3 ADRB1 16/4885HTR6 322/4885HTR7 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.